A federal judge is extending a temporary restraining order against the Trump administration’s cuts to overhead research funds ...

National Institutes of Health (NIH) Acting Director Matthew Memoli sought to clarify the extent of the Trump administration's freeze on communications and other functions within the Health and ...

titled “NIH Intramural Research Program Access Planning Policy.” The Bayh-Dole Coalition’s issue brief drew specific attention to “the requirement that prospective licensees explain to NIH ...

"Procurement, contracting, traveling and hiring at NIH are continuing for anything directly related to human safety, human or animal healthcare, security, biosafety, biosecurity and IT security ...

A new memo by NIH Acting Director Matthew Memoli, obtained by Forbes, clarifies what can and can’t be done with regard to clinical trials, purchasing, research publications and public appearances.

Oregon in 2023 raked in $428 million in grants from NIH, a little less than the peak of $436 million in 2020. The agency's grants generate $992 million in economic activity in the state and ...

Last week, many scientists expressed alarm that the Trump administration had suspended most operations at NIH, which provides grants for scientific research at universities across the country.

WASHINGTON — The National Institutes of Health’s myriad divisions can start new work on mission-critical research, and continue working on ongoing studies, but cannot publicly communicate ...

On January 22, 2025, the US scientific community woke up to the abrupt and startling announcement that the Trump administration has imposed numerous restrictions on the National Institutes of Health ...

Duke received more than $580 million and UNC saw just north of $531 million in NIH funding, according to figures from NIH. Each received more than 1,000 grants during that time. The only other ...

Though Memoli is an NIH insider, one source familiar with him noted his perspectives —particularly his opposition to Covid-19 vaccine mandates — make him more of an outsider at the agency.

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. The Trump ...